CD79B - morinlab/LLMPP GitHub Wiki
bibliography: 'morinlab.bib' csl: 'NLM.csl' link-citations: true nocite: | @flumannInducibleCd79bMutation2024, @wrightProbabilisticClassificationTool2020, @morinFrequentMutationHistonemodifying2011, @davisChronicActiveBcellreceptor2010, @wilsonEffectIbrutinibRCHOP2021, @kimCD79BMYD88Mutations2014, @paneaWholeGenomeLandscape2019,
Overview
CD79B mutations significantly contribute to the pathogenesis of DLBCL by enhancing BCR signaling and promoting tumor survival. These mutations, especially when co-occurring with MYD88 mutations, define a unique molecular subtype.[@wrightProbabilisticClassificationTool2020] This has clinical and therapeutic implications as it may contribute sensitivity to BTK inhibitors. In an inducible mouse model of MYD88-driven DLBCL, CD79B mutations did not accelerate lymphomagenesis but demonstrated an increased sensitivity to pharmacological BTK inhibition.[@flumannInducibleCd79bMutation2024] In a retrospective analysis, younger patients with MCD DLBCL that were treated with ibrutinib had significantly better outcomes.[@wilsonEffectIbrutinibRCHOP2021] The most common hotspot mutation in CD79B is at the tyrosine residue 196 (Y196). This and other common mutations primarily occur in the immunoreceptor tyrosine-based activation motif (ITAM) domain and prevent the negative regulatory feedback provided by Lyn kinase thereby enhancing BCR signaling.[@kimCD79BMYD88Mutations2014; @davisChronicActiveBcellreceptor2010]
Experimental Evidence
Driver mutations affecting this gene in DLBCL have been experimentally demonstrated to cause a gain of function (GOF).[@davisChronicActiveBcellreceptor2010]
Relevance tier by entity
include:tables/table1_CD79B.md
Mutation incidence in large patient cohorts (GAMBL reanalysis)
DLBCL
FL
Mutation pattern and selective pressure estimates
CD79B Hotspots
Mutations at Y196 enhance B-cell receptor (BCR) signaling by preventing the negative regulatory feedback provided by Lyn kinase, a feedback inhibitor of BCR signaling. This results in continuous activation of the NF-ÎșB pathway, promoting tumor cell survival and proliferation.[@kimCD79BMYD88Mutations2014]
Chromosome | Coordinate (hg19) | ref>alt | HGVSp |
---|---|---|---|
chr17 | 62007234 | C>G | A150P |
chr17 | 62007234 | C>T | A150T |
chr17 | 62007233 | G>A | A150V |
chr17 | 62007140 | A>G | L181P |
chr17 | 62007129 | C>T | X184_splice |
chr17 | 62006798 | T>A | Y197F |
chr17 | 62006798 | T>C | Y197C |
chr17 | 62006799 | A>C | Y197D |
chr17 | 62006799 | A>G | Y197H |
chr17 | 62006798 | T>G | Y197S |
chr17 | 62006795 | T>C | E198G |
chr17 | 62006680 | A>G | L200P |
chr17 | 62006680 | A>C | L200R |
chr17 | 62006680 | A>T | L200Q |
chr17 | 62006603 | G>A | H226Y |
chr17 | 62006603 | G>T | H226N |
include:tables/browser_CD79B.md
Expression
Representative Mutations
BL
Rating
â â â â â
Rating
â
â
â
â â
include:tables/mermaid_CD79B.md